What Is Opioid Use Disorder and How Is Methadone Treatment Used?

Opioid use disorder (OUD) is a medical condition. It develops when a person becomes dependent on opioids, a class of drugs that includes prescription painkillers such as oxycodone and codeine, as well as illicit substances like heroin and fentanyl. Methadone treatment is one of the most established responses to this condition. In the United States, opioid overdose remains a serious public health crisis, and understanding how treatment works matters for everyone.

Methadone significantly reduces the risk of fatal overdose. It also lowers all-cause mortality among people with OUD. It works by reducing cravings and withdrawal symptoms, helping people stabilise their lives and step back from opioid use.

Yet despite its proven effectiveness, methadone is one of the most tightly restricted medications in the country. Understanding why reveals a great deal about the barriers that separate people with addiction from the care they need.

How Methadone Access Currently Works (and Why It Falls Short)

Under current US federal law, only federally certified opioid treatment programmes (OTPs) can dispense methadone for OUD. There are approximately 2,100 OTPs across the United States. Even so, 80% of US counties have no OTP at all, and the entire state of Wyoming has none.

For people in rural communities, reaching treatment can mean driving nearly two hours each way, every single day. Research shows that people who live further from their treatment programme are less likely to stay in it. That link between distance and dropout is not a minor inconvenience. It can be a matter of life and death.

Beyond geography, OTPs often present other obstacles. Long waiting lists, limited operating hours, and facilities that may not be welcoming to parents with young children all push people away. These barriers discourage many from starting treatment, even when they genuinely want to.

Could Pharmacies Change the Picture for Methadone Treatment Access?

A peer-reviewed economic study published in JAMA Network Open in March 2026 asked a straightforward question: could community pharmacies help expand methadone treatment access?

Researchers at Brandeis University and Boston University School of Public Health modelled two pharmacy-based approaches.

The first is the medication unit model. An OTP partners with a local pharmacy to run a satellite dispensing site. OTP clinicians continue to prescribe and oversee treatment. The pharmacist dispenses the medication on site. Patients still belong to the OTP but collect their methadone at the pharmacy.

The second is the pharmacist-dispensed model. This would require a change to federal regulations. A DEA-registered clinician would prescribe methadone. A pharmacist would then dispense it, much as they already do with other controlled medications.

Why does pharmacy access matter? Nearly 50% of rural census tracts in the US have a community pharmacy within a 20-minute drive. Far fewer have an OTP nearby. Pharmacists have dispensed methadone for pain relief for decades. They already fill prescriptions for other OUD medications, including buprenorphine and naltrexone. In many places, the infrastructure already exists.

What the Research Found

The Brandeis study ran 10,000 computer simulations. It tested best-case, worst-case, and moderate financial scenarios for pharmacies under each model.

For the medication unit model, pharmacies could return $3.53 for every $1.00 invested over three years. That translates to a net profit of approximately $96,900. There is a 93.8% probability of netting at least $15,000 by year three.

For the pharmacist-dispensed model, the projected return is $2.64 for every $1.00 spent. The estimated net profit is around $23,800. There is a 97.6% chance of reaching the $15,000 threshold.

Both models show a positive return on investment. Expanding methadone treatment access through pharmacies looks financially viable, not just theoretically sound.

One note of caution: the medication unit model carries more financial uncertainty. Under less favourable assumptions, there is a 25.3% chance of loss. The pharmacist-dispensed model shows a 25.9% chance of loss under similarly conservative conditions. Pharmacy owners would need to assess local demand, costs, and partnership terms carefully before making a decision.

The Barriers That Remain

The research is encouraging, but the path forward is not simple.

The medication unit model is already legal under federal law in most states. Yet few pharmacies have pursued it. Regulations are unclear and complex. Many pharmacy owners do not know the option exists. Some states ban medication units outright. There is also a requirement to store methadone entirely separately from all other controlled substances. That adds administrative burden and cost.

The pharmacist-dispensed model faces a higher bar. It requires either a regulatory shift from the Drug Enforcement Administration or new legislation to amend the Controlled Substances Act. Patient groups, addiction medicine clinicians, and pharmacy organisations have increasingly called for this change. But it remains a significant policy hurdle.

There is also a broader concern worth stating plainly. When treatment access depends on geography, regulation, and financial incentive more than on clinical need, people in poverty and rural areas bear the greatest cost. They are the ones most often left without care.

What This Means for Communities and Policy

Opioid use disorder does not exist in isolation. It clusters in communities that are already under-resourced. Treatment gaps carry serious consequences, not only for individuals but also for families, workplaces, and public health.

For policymakers, the implications are clear. States can incentivise pharmacy participation through tiered dispensing fees, meaning higher reimbursement for pharmacies in rural or low-income areas. Opioid settlement funds, distributed to states in significant sums in recent years, could support pharmacy and OTP partnerships. Recognising pharmacists as clinicians for billing purposes would also open doors for expanded services.

For pharmacy owners, particularly those operating independently in underserved communities, the financial case now has evidence behind it. The 2026 research gives the sector something it has long lacked: a clear economic framework for evaluating whether expanding into methadone treatment access is worth pursuing.

Prevention of opioid dependence is the most powerful intervention of all. But for those already in the grip of addiction, reliable access to evidence-based treatment is not optional. It is essential.

Source: jamanetwork